Latigo Biotherapeutics, Inc.
LTGONasdaqCIK 2056611HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$27.59Diluted EPS, Q2 FY2026, three months to 2026-06-30−$27.59 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure+24.5% on a year earlier - Free cash flownot reported (Operating cash flow and Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | period not labelled2026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | not reported (Diluted EPS not reported) | (36.52)Diluted EPS, period not labelled, three months to 2025-06-30−$36.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported (Diluted EPS not reported) | (27.59)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$27.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | |
| Free cash flow | $ | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
None of the funds in coverage reports a position in this company in its latest 13F.
Recent filings
All 39 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0316:32 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-381969 |
| 2026-09-0316:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-381912 |
| 2026-08-1719:06 ET | SCHEDULE 13D | Ownership report, active investor | 0001104659-26-097980 |
| 2026-08-1016:02 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-342321 |
| 2026-08-0421:54 ET | S-1/A | Registration statement, amended | 0001193125-26-331205 |
| 2026-08-0306:06 ET | S-1/A | Registration statement, amended | 0001193125-26-329431 |
| 2026-07-1712:33 ET | S-1 | Registration statement | 0001193125-26-307306 |
Latest annual report
No annual report is in coverage for this company.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 2056611
- Tickers
- LTGO
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:05 ET. Listed shows no prices and gives no investment advice.